Midostaurin cut organ damage in systemic mastocytosis

Midostaurin completely resolved at least one type of organ damage for 45% of patients with advanced systemic mastocytosis, based on a multicenter, open-label, phase II, industry-sponsored trial....
Source: Hospitalist News - Category: Hospital Management Source Type: research